Amendment: SEC Form SC 13G/A filed by Dyne Therapeutics Inc.
$DYN
Biotechnology: Pharmaceutical Preparations
Health Care
Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/24/2025 | $13.00 | Mkt Perform | Bernstein |
| 6/11/2025 | $37.00 | Outperform | Raymond James |
| 6/2/2025 | $34.00 | Outperform | Oppenheimer |
| 5/29/2025 | $46.00 | Outperform | Evercore ISI |
| 3/12/2025 | $50.00 | Outperform | BMO Capital Markets |
| 3/7/2025 | $50.00 | Sector Outperform | Scotiabank |
| 12/13/2024 | $46.00 | Outperform | Robert W. Baird |
| 11/26/2024 | $45.00 | Outperform | RBC Capital Mkts |
4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)
4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)
4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)
4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)
4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)
4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)
Bernstein initiated coverage of Dyne Therapeutics with a rating of Mkt Perform and set a new price target of $13.00
Raymond James resumed coverage of Dyne Therapeutics with a rating of Outperform and set a new price target of $37.00
Oppenheimer resumed coverage of Dyne Therapeutics with a rating of Outperform and set a new price target of $34.00
424B5 - Dyne Therapeutics, Inc. (0001818794) (Filer)
8-K - Dyne Therapeutics, Inc. (0001818794) (Filer)
424B5 - Dyne Therapeutics, Inc. (0001818794) (Filer)
SC 13G/A - Dyne Therapeutics, Inc. (0001818794) (Subject)
SC 13G/A - Dyne Therapeutics, Inc. (0001818794) (Subject)
SC 13G/A - Dyne Therapeutics, Inc. (0001818794) (Subject)
Brings a successful track record in clinical development and regulatory approval of innovative neuromuscular therapies Satellos Bioscience Inc. (TSX:MSCL, OTCQB:MSCLF) ("Satellos" or the "Company"), a biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases, today announced the appointment of Wildon Farwell, M.D., MPH, as chief medical officer ("CMO"). Dr. Farwell joins Satellos from Dyne Therapeutics (NASDAQ:DYN), where he most recently served as CMO and medical advisor. "We are thrilled to welcome Dr. Farwell as our CMO," said Frank Gleeson, Satellos co-founder and CEO. "He brings deep expertise in global clinical development — p
WALTHAM, Mass., July 02, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced the closing of its previously announced underwritten public offering of 27,878,788 shares of its common stock at a public offering price of $8.25 per share, which includes 3,636,363 shares issued upon the exercise in full by the underwriters of their option to purchase additional shares of common stock in the offering. The gross proceeds to Dyne from the offering were approximately $230.0 million, before deducting underwriting discounts and commissions a
WALTHAM, Mass., June 30, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced the pricing of an underwritten public offering of 24,242,425 shares of its common stock at a public offering price of $8.25 per share. The gross proceeds to Dyne from the offering, before deducting underwriting discounts and commissions and offering expenses payable by Dyne, are expected to be $200.0 million. All shares in the offering are being sold by Dyne. The offering is expected to close on or about July 2, 2025, subject to customary closing conditi
- Based on Type C meeting and new data, Dyne submitted revised ACHIEVE trial protocol to FDA elevating vHOT to primary endpoint for U.S. Accelerated Approval - - New positive clinical data from Phase 1/2 ACHIEVE trial support vHOT as early indicator of clinical benefit with DYNE-101 in DM1 - - Ongoing Registrational Expansion Cohort in ACHIEVE trial to enroll 60 participants and include sites in U.S. - - Company to host an investor and analyst conference call today, June 17, at 8:00 a.m. ET - WALTHAM, Mass., June 17, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically
WALTHAM, Mass., June 16, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage neuromuscular disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced it plans to provide an update on DYNE-101 in myotonic dystrophy type 1 (DM1) tomorrow, June 17, 2025, and to host a webcast at 8:00 a.m. ET. The company intends to issue a press release prior to the start of the event. Investor Conference Call and Webcast The live webcast will be available on the Events & Presentations page of the Investors & Media section of Dyne's website, and a replay will be accessible for 90 days followin
- DYNE-101 in DM1: Dyne plans to initiate global Registrational Expansion Cohort of ACHIEVE trial with registrational dose of 6.8 mg/kg Q8W following study data showing splicing correction and robust and sustained functional improvements; potential to support H1 2026 submission for U.S. Accelerated Approval - - DYNE-251 in Exon 51 DMD: Based on recent FDA feedback, pursuing U.S. Accelerated Approval with dystrophin as surrogate endpoint; data from ongoing Registrational Expansion Cohort in DELIVER trial expected late 2025 with potential to support early 2026 regulatory submission - - Investor event today, January 10th at 8:00 a.m. ET - WALTHAM, Mass., Jan. 10, 2025 (GLOBE NE
Brings a successful track record in clinical development and regulatory approval of innovative neuromuscular therapies Satellos Bioscience Inc. (TSX:MSCL, OTCQB:MSCLF) ("Satellos" or the "Company"), a biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases, today announced the appointment of Wildon Farwell, M.D., MPH, as chief medical officer ("CMO"). Dr. Farwell joins Satellos from Dyne Therapeutics (NASDAQ:DYN), where he most recently served as CMO and medical advisor. "We are thrilled to welcome Dr. Farwell as our CMO," said Frank Gleeson, Satellos co-founder and CEO. "He brings deep expertise in global clinical development — p
- John Cox, Industry Leader with Global Experience in Rare Disease Commercialization, Joins Dyne as President and CEO - WALTHAM, Mass., March 25, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced the appointment of John Cox as president, chief executive officer (CEO) and a member of the Board of Directors, effective immediately. He succeeds Joshua Brumm, who has chosen to step down from these roles to pursue a career in healthcare investing. Mr. Brumm will serve as an advisor to Dyne to help ensure a seamles
- Appointment Expands Dyne's Development Team as Company Advances Multiple Programs into Clinical Trials - WALTHAM, Mass., Aug. 29, 2022 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced the appointment of Francesco Bibbiani, M.D., as senior vice president, head of development. Dr. Bibbiani brings more than two decades of experience across development, including a focus on rare neuromuscular diseases as well as Duchenne muscular dystrophy (DMD). "We are excited to welcome Francesco to Dyne's development